GHK-Cu

Also known as: Copper peptide, Copper tripeptide-1

GHK-Cu (copper tripeptide-1) is a naturally occurring copper-binding tripeptide (glycyl-histidyl-lysine) that exerts its effects primarily through modulation of gene expression related to extracellular matrix remodeling. Its mechanism involves chelating copper ions, which facilitates activation of matrix metalloproteinases and upregulation of collagen synthesis, angiogenesis, and antioxidant enzyme activity. GHK-Cu also influences transforming growth factor-beta (TGF-β) signaling pathways, promoting fibroblast proliferation and migration, while reducing inflammation and oxidative stress in tissue microenvironments. Preclinical studies (72 PubMed references) demonstrate that GHK-Cu accelerates wound closure in animal models, increases dermal collagen deposition, and improves tensile strength of healed tissue. In vitro, it enhances fibroblast and keratinocyte proliferation, reduces interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) levels, and upregulates genes for decorin, versican, and other proteoglycans. Research also indicates neuroprotective and anti-aging properties, including reduction of DNA damage and promotion of neural stem cell differentiation. Clinically, GHK-Cu is widely used in topical cosmetic formulations for skin rejuvenation and scar reduction, though its therapeutic applications remain preclinical. No large-scale human trials have validated efficacy for systemic conditions such as chronic wounds or fibrosis. The peptide's safety profile is favorable in topical use, but systemic administration requires further investigation. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides